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Abstract
Since the beginning of the 20th century, humans have experienced four influenza pandemics, including the
devastating 1918 ‘Spanish influenza’. Moreover, H5N1 highly pathogenic avian influenza (HPAI) viruses are currently
spreading worldwide, although they are not yet efficiently transmitted among humans. While the threat of a global
pandemic involving a highly pathogenic influenza virus strain looms large, our mechanisms to address such a
catastrophe remain limited. Here, we show that pre-stimulation of Toll-like receptors (TLRs) 2 and 4 increased
resistance against influenza viruses known to induce high pathogenicity in animal models. Our data emphasize the
complexity of the host response against different influenza viruses, and suggest that TLR agonists might be utilized
to protect against lethality associated with highly pathogenic influenza virus infection in humans.
Background
During the 20th century, humans experienced three
influenza pandemics, each resulting in significant glo-
bal mortality: 20 to 40 million deaths in 1918 (Spanish
influenza), 1 to 4 million deaths in 1957 (Asian influ-
enza), and 1 to 4 million deaths in 1968 (Hong Kong
influenza) [1]. In addition, the pandemic (H1N1) 2009
virus has spread rapidly around the world since spring
of 2009; and HPAI viruses have been circulating
worldwide since late 2003. Although HPAI viruses
are not yet efficiently transmitted to or among
humans, their sustained proliferation and continued
genetic evolution in avian species, combined with par-
allel infections in humans, makes this an eventual
possibility.
Some patients infected with either 2009 pandemic
H1N1 or HPAI viruses develop acute respiratory dis-
tress syndrome and severe alveolar damage [2-5]. This
pathologic condition is associated with a strong upre-
gulation of cytokines and chemokines: in particular,
interferon-induced protein 10 (IP-10; CXCL10),
monokine induced by interferon gamma (MIG;
CXCL9), monocyte chemotactic protein 1 (MCP-1;
CCL2), interleukin (IL)-8, IL-10, IL-6, interferon g
(IFN-g), and tumor necrosis factor a (TNF-a) [6-10].
In the macaque model, infection with the 1918 Spanish
influenza virus markedly increased serum levels of IL-
6, IL-8, MCP-1, and RANTES (RANTES; CCL5) [11].
Thus, it has been suggested that the severity of influ-
enza is associated with the aberrant induction of innate
immunity.
Pre-stimulation of innate immunity has been shown to
confer resistance against lethal influenza infection.
Specifically, influenza A virus titers decreased in cells
pre-treated with TNF-a, and inoculation of mice with
bacterial lysates before viral infection protects against
lethal influenza pneumonia [12-15]. Moreover, the gen-
eral stimulation of innate immunity with interferon a,
as well as the stimulation of specific Toll-like receptors
(TLRs), promotes survival in mouse models of lethal
influenza pneumonia [16-19]. However, the ability of
innate immunity pre-stimulation to attenuate disease
associated with HPAI viruses has not been explored. In
the present study, we aimed to determine the protective
effects of TLR pre-stimulation in mice inoculated with
influenza A viruses.
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Cell lines
Madin-Darby canine kidney (MDCK) cells were main-
tained in Dulbecco’sm o d i f i e dE a g l e ’s medium (DMEM)
supplemented with 10% fetal calf serum, and 293T
human embryonic kidney cells were maintained in mini-
mal essential medium (MEM) with 5% newborn calf
serum. All cells were maintained at 37°C in an atmo-
sphere of 5% CO2.
Viruses
Influenza A/Puerto Rico/8/34 (PR8; H1N1) and A/Viet-
nam/1203/04 (VN1203; H5N1) stock viruses were pre-
pared in 10-day-old embryonated chicken eggs or
MDCK cells, respectively. After MDCK cells were inocu-
lated with influenza virus, they were grown in MEM
containing 0.3% BSA with TPCK-trypsin (0.5 ug/ml) to
propagate PR8 or without TPCK-trypsin to propagate
VN1203. One reassortant virus was generated from plas-
mids by reverse genetics, as described previously [20,21].
The reassortant possessed the hemagglutinin (HA) seg-
ment from influenza A/South Carolina/1918 (H1N1)
and the remaining seven viral RNA segments from
influenza A/WSN/33 (H1N1), and was designated
SpHA/WSN. The SpHA/WSN transfectant produced in
293T cells were used to inoculate MDCK cells for stock
virus production. Stock virus titers were determined by
the median egg infectious dose (EID50) or plaque assay.
Experiments using VN1203 or SpHA/WSN were con-
ducted in an enhanced biosafety level 3 (BSL3+) con-
tainment laboratory approved for such use by the
Centers for Disease Control and Prevention and the
United States Department of Agriculture.
Lethal dose studies in mice
BALB/c mice (6-week-old) used in this study were
maintained in a specific pathogen-free environment. All
manipulations (TLR pre-treatments and virus inocula-
tions) were performed in mice anesthetized with sevo-
flurane. Pre-treatments with the indicated TLR ligands
were carried out by intranasal administration of 100 μl
phosphate-buffered saline (PBS) containing these ligands
at the indicated times before infection. Control mice
were inoculated with PBS only. To determine the mouse
lethal dose 50 (MLD50) following pre-stimulation,
anesthetized BALB/c mice were intranasally inoculated
with 10-fold serial dilutions of virus in 50 μl PBS (each
group, n = 3). Mice were monitored daily over 14 days
for disease symptoms and survival, and the MLD50 value
was calculated according to the method of Reed and
Muench [22]. To minimize the number of animals used
for these experiments, we performed each MLD50 titra-
tion once. Animal care and experimental procedures
were approved by the Animal Research Committees at
Tohoku University and the University of Wisconsin-
Madison.
TLR ligand pre-treatment in mice
For initial MLD50 determination with PR8, we used LPS
from Escherichia coli (E. coli) serotype O26:B6 (Sigma,
Tokyo; catalog #L8274) at 2.5, 1.25, 0.625, 0.3125, or
0.15625 mg/kg. For subsequent MLD50 experiments
comparing the antiviral effects of stimulating different
TLRs, we used the following TLR ligands from Invivo-
Gen (San Diego, CA, USA): synthetic mycoplasmal lipo-
protein (FSL-1, 50 μg/kg; cat# tlrl-fsl) as the TLR2
ligand; analog of dsRNA (Poly(I:C), 1.25 mg/kg; cat#
tlrl-pic) as the TLR3 ligand; LPS from E. coli K12 msbB
strain (2.5 mg/kg; cat# tlrl-mklps) and LPS from E. coli
serotype O111:B4 (2.5 mg/kg; cat# tlrl-pelps) as TLR4
ligands; and a guanosine analog (loxoribine, 2.5 mg/kg;
cat# tlrl-lox) as the TLR7 ligand.
Results
TLR4 prestimulation with lipopolysaccharide protects
mice against lethal influenza virus challenge
Mice pretreated with a bacterial cell lysate, which induced
robust inflammation likely through LPS-dependent activa-
tion of the TLR4 pathway, were more likely to survive a
lethal influenza virus challenge [15]. Similarly, specific
activation of the TLR4 pathway with synthetic agonists
protected mice against influenza-induced lethality [17]. To
establish our experimental system of pre-stimulation with
the well-characterized TLR4 ligand LPS, we intranasally
pre-treated BALB/c mice with LPS (Escherichia coli sero-
type O26:B6; 2.5, 1.25, 0.625, 0.3125, or 0.15625 mg/kg) at
various times (12 or 24 hours, or 3 or 7 days) before expo-
sure to influenza virus. LPS-treated mice were then
infected with PR8, and the MLD50 was calculated for each
experimental group. Results were expressed as the differ-
ence between the MLD50 of each treatment group and
that of a control group (Table 1). Although some protec-
tion was afforded by LPS pre-treatment at all time points,
the most effective pre-treatment time was 3 days before
infection, when all LPS dosages increased the MLD50 by at
least 10-fold. Overall, pre-treatment with 1.25 mg/kg LPS
at 3 days before infection provided the best protection.
Protective effects of pre-stimulation of various TLRs
Several reports have indicated that mice intranasally pre-
treated with TLR ligands other than those for TLR4 exhi-
bit enhanced survival when challenged with influenza
virus [18,19,23]. We therefore compared several different
TLR ligands to determine which would best protect
against a lethal influenza virus challenge. We evaluated the
effects of pre-stimulation of surface-expressed TLRs
(TLR2 and TLR4) and endosomal TLRs (TLR3 and TLR7)
using the following ligands: synthetic mycoplasmal
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dsRNA (Poly(I:C); 1.25 mg/kg) for TLR3; LPS from E. coli
K12 msbB strain (2.5 mg/kg) for weak TLR4 stimulation;
purified LPS from E. coli serotype O111:B4 (2.5 mg/kg) for
normal TLR4 stimulation; and the guanosine analog loxor-
ibine (2.5 mg/kg) for TLR7. Mice pre-treated with TLR-
specific ligands were challenged 3 days later with serial
dilutions of PR8, and the difference in MLD50 was calcu-
lated for each experimental group and compared to PBS-
treated controls (Table 2). As expected, all TLR ligands
protected against lethal influenza pneumonia, but pre-
stimulation with FSL-1 (TLR2 ligand) or msbB LPS (weak
TLR4 agonist) provided the best protection, both produ-
cing a 10-fold increase in MLD50. These findings demon-
strate that TLR4 pre-stimulation is more effective using a
weak TLR4 agonist, and support the hypothesis that lung
cells express both TLR2 and TLR4 [24].
Differential effects of TLR prestimulation on lethal
pneumonia associated with highly pathogenic influenza
viruses in mice
We hypothesized that TLR prestimulation-mediated
protection against lethal infection by a mouse-adapted
influenza strain could extend to influenza virus strains
that induce high pathogenicity. To test this hypothesis,
we infected mice with or without either TLR2 or TLR4
pre-stimulation with an HPAI H5N1 virus isolate
(VN1203) or a reassortant virus possessing the hemag-
glutinin (HA) gene segment from the 1918 Spanish
influenza virus (SpHA/WSN) (Table 3). The high patho-
genicity of these virus strains was previously demon-
strated in mice [20,25].
We observed a difference in the ability of TLR2 and
TLR4 pre-stimulation to protect against highly patho-
genic viruses. Consistent with protection against PR8 in
LPS-pretreated mice, TLR4 stimulation with msbB LPS
(weak agonist) protected against lethality induced by
VN1203 (10-fold increase in MLD50 compared to
untreated control). In contrast, TLR2 stimulation with
FSL-1 did not protect against VN1203 (Table 3). How-
ever, we observed the opposite pattern with SpHA/WSN:
TLR2 pre-stimulation conferred better protection against
lethality compared to TLR4 pre-stimulation. These
results suggest that the best method of stimulating innate
immunity depends on the particular virus in question.
Table 1 Antiviral effect of intranasal prestimulation by
lipopolysaccharide against influenza A/Puerto Rico/8/34
LPS
(mg/kg)
a
Pretreatment
time
Ratio of MLD50 (log10EID50) between
LPS-pretreated and mock-treated mice
b
0.15625 7 days 0
3 days 1.0
24 hrs 0
12 hrs 0
0.3125 7 days 0.6
3 days 1.26
24 hrs 0
12 hrs 0
0.625 7 days 1.0
3 days 1.6
24 hrs 1.0
12 hrs 0.3
1.25 7 days 0
3 days 1.94
24 hrs 0.94
12 hrs 0.94
6 hrs 0.24
2.5 7 days 1.0
3 days 1.3
24 hrs 1.0
12 hrs 0
aEscherichia coli (serotype O26:B6)-derived lipopolysaccharide (LPS), MLD50 =
36.4 (mg/kg)
b “0” would be no difference and “1.0” would indicate that 10 times more
virus is need to kill 50% of infected animals when treated with the indicated
amount of LPS.
Table 2 Antiviral effect of prestimulation with Toll-like
receptor specific ligands against influenza A/Puerto Rico/
8/34
TLR ligand Receptor Ratio of MLD50 (log10EID50)
between LPS-pretreated and
mock-treated mice
Synthetic
mycoplasmal
lipoprotein (FSL-1)
TLR2 1.0
Synthetic analog of
dsRNA (Poly(I:C))
TLR3 0.66
LPS from E. coli K12
msbB
TLR4 1.0
LPS from E. coli
serotype O111:B4
0.66
Guanosine analog
(loxoribine)
TLR7 0.66
Table 3 Antiviral effect of prestimulation by Toll-like
receptor-specific ligands
TLR stimulation Virus strain Ratio of MLD50 (log10EID50)
between LPS-pretreated and
mock-treated mice
TLR2
a A/Vietnam/1203/04 0
TLR4
b A/Vietnam/1203/04 1.0
TLR2 Sp HA/WSN
c 0.76
TLR4 Sp HA/WSN
c 0.49
aSynthetic mycoplasmal lipoprotein (FSL-1).
bLPS of E. coli K12 msbB (LPS agonist).
cReassortant possessing the HA segment from influenza A/South Carolina/
1918 (H1N1) and the remaining seven viral RNA segments from A/WSN/33
(H1N1).
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Our results indicate that TLR pre-stimulation protects
mice from lethal challenge with highly pathogenic influ-
enza viruses. Although previous reports have suggested
the efficacy of TLR pre-stimulation in promoting survi-
val after influenza challenge [15,17], we provide the first
evidence that TLR activation is effective against HPAI
and other highly pathogenic influenza strains.
Inactivated H5N1 virus has been shown to induce acute
lung injury through the TLR4-TRIF pathway [26], suggest-
ing that viral surface glycoproteins HA and/or neuramini-
dase (NA), may be sensed by TLR4 on the cell surface.
TLR4 responds to molecular signatures of microbial origin
(i.e., LPS), but more recent evidence suggests that TLR4
can also be activated by viral infection [27-29]. Thus,
robust replication and expression of viral antigens may
induce hyperactivation of the TLR4 signaling pathway and
lead to lung injury; the H5N1 virus is not likely to be an
exception. Our data showed that TLR4 pre-stimulation
could also offer protection against lethal HPAI infections.
It is interesting that a molecule associated with influenza
severity can also protect against influenza-induced lethality
when given prophylactically.
While pre-stimulation of both TLR2 and TLR4 signal-
ing pathways protected against the PR8 virus, protection
against the VN1203 virus could only be achieved by
TLR4 pre-stimulation. Contrastingly, a virus carrying
the 1918 Spanish influenza HA molecule was not inhib-
ited by a TLR4 agonist, but rather was more affected by
pre-stimulation of TLR2. TLR2 and TLR4 induce over-
lapping and unique signaling associated with innate
immunity, and these pathways may be differentially
required for protection against different influenza
viruses. We suggest that TLR4-mediated signaling may
have a principle role in protection against HPAI viruses,
while control of Spanish influenza may involve TLR2-
related mechanisms. Our data highlights the complex
nature of innate signaling in response to infection with
different influenza virus strains, and emphasizes the
need for further dissection of the pathways that are
involved in controlling influenza infection and promot-
ing influenza pathogenesis. Further, we suggest that this
information could be utilized in the development of
countermeasures against highly pathogenic influenza
virus infections in humans.
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